Skip to content
lifestyle.friendhood.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cognition Therapeutics, Inc.
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
August 6, 2026
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities’ Mind, Muscle & Vision Summit
July 13, 2026
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
June 24, 2026
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
June 16, 2026
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
May 7, 2026
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
April 7, 2026
Cognition Therapeutics CEO Issues Letter to Shareholders
March 31, 2026
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
March 26, 2026
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
March 23, 2026
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
March 17, 2026
1
2
Next Page
→